8-K ·Filed Oct 29, 2026
8-K context-dependent: Items 7.01
Actionable Insight • Neutral
Monitor the November 5 presentation for Q3 revenue and cash burn trends, which are key for a pre-revenue biotech platform company with a $725M market cap and heavy insider selling in the prior month.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1Entry
$11.21
T+0 close · Oct 29, 2026 · via day close
Latest settled
−12.13%
T+1 · $9.85
vs SPY
−11.65%
α at T+1
Next horizon
T+5
due 14h ago
- T+0 · Oct 29 $11.21entry
- T+1 · 7d ago −12.13%α −11.65% · $9.85
- T+5 · due 14h ago Pending
- T+5 · todayOpen
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
Loading chart...
How similar events traded
Executive Summary
Ginkgo Bioworks filed an 8-K announcing the date of its Q3 2026 earnings presentation and Q&A session, scheduled for November 5, 2026 after market close. The filing contains no financial results, guidance, or material operational updates.
Key Facts
- Ginkgo will host a Q3 2026 results presentation on Thursday, November 5, 2026 at 4:30 p.m. ET
- The presentation will be available via webcast on the company's investor relations website
- No preliminary financial results or guidance were disclosed in this filing
Financial Impact
No financial data provided in the filing
Risk Factors
- No financial data or guidance was released, leaving uncertainty about Q3 performance until the November 5 event
- The stock has a high normal daily move of 9.5%, indicating elevated volatility expectations
Market Snapshot
Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (10 analysts)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-068220 |
| Document: q32026announcement.htm | 0001628280-26-068220 |
| Document: 0001628280-26-068220-index-headers.html | 0001628280-26-068220 |
| Document: 0001628280-26-068220-index.html | 0001628280-26-068220 |
| Document: 0001628280-26-068220.txt | 0001628280-26-068220 |
7 reports for DNA
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 5, 2026 today | 8-K | $11.00 | awaiting T+60 | awaiting T+60 | $11.65 (+5.91%) |
Oct 29, 2026 7d ago | 8-K | $11.21 | awaiting T+60 | awaiting T+60 | $11.65 (+3.93%) |
Oct 21, 2026 15d ago | Insider Cluster | $9.71 | awaiting T+60 | awaiting T+60 | $11.65 (+19.98%) |
Oct 19, 2026 17d ago | 144 | $10.07 | awaiting T+60 | awaiting T+60 | $11.65 (+15.69%) |
Sep 15, 2026 7w ago | 144 | $6.99 | awaiting T+60 | awaiting T+60 | $11.65 (+66.67%) |
Apr 9, 2026 30w ago | Insider Cluster | $6.43 $10.11 | ▼ −57.23% | ▼ −46.45% | $11.65 (−81.18%) |
Apr 9, 2026 30w ago | Insider Cluster | $6.43 $10.11 | ▼ −57.23% | ▼ −46.45% | $11.65 (−81.18%) |
Showing 7 of 7
US Market Status
Market Closed · Opens Mon (60h 53m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers